

## AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior claims presented in the application.

1-13. (Canceled)

14. (Currently amended) A method for ~~delaying or inhibiting or suppressing~~ the accumulation of an amyloid  $\beta$  peptide or fragment thereof in the brain, comprising the step of administering to a subject in need of such inhibition an antibody which is targeted to an amyloid  $\beta$  peptide, or to fragment thereof, thereby ~~delaying or inhibiting or suppressing~~ accumulation of said amyloid  $\beta$  peptide or fragment thereof in the brain of said subject.

15. (Canceled)

16. (Original) The method of claim 14, wherein the antibody is directed to N-terminus-truncated amyloid  $\beta$  peptide fragment.

17. (Original) The method of claim 14, wherein the antibody is directed to C-terminus-truncated amyloid  $\beta$  peptide fragment.

18. (Original) The method of claim 14, wherein the antibody is directed to the amyloid precursor protein, or fragment thereof.

19. (Original) The method of claim 14, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

20. (Currently amended) A method for ~~delaying or inhibiting or suppressing~~ the neurotoxicity of amyloid  $\beta$  peptide or fragment thereof, comprising the step of administering to a subject in need of such inhibition an antibody which is targeted to amyloid  $\beta$  peptide, or fragment thereof, thereby ~~delaying or inhibiting or suppressing~~ the neurotoxicity of amyloid  $\beta$  peptide or fragment thereof in said subject.

21. (Canceled)

22. (Original) The method of claim 20, wherein the antibody is directed to N-terminus-truncated amyloid  $\beta$  peptide fragment.

23. (Original) The method of claim 20, wherein the antibody is directed to C-terminus-truncated amyloid  $\beta$  peptide fragment.

24. (Original) The method of claim 20, wherein the antibody is directed to the amyloid precursor protein, or fragment thereof.

25. (Original) The method of claim 20, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

26-50. (Canceled)

51. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and targeted to the free N-terminus of amyloid  $\beta$ -peptide or a fragment thereof for  
~~delaying or inhibiting or suppressing the accumulation of an amyloid  $\beta$ -peptide or fragment thereof,~~  
~~comprising the step of administering the antibody of claim 26, thereby delaying or inhibiting or~~  
~~suppressing accumulation of amyloid  $\beta$ -peptide or fragment thereof in the brain.~~

52. (Currently amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and targeted to the free N-terminus of amyloid  $\beta$ -peptide or a fragment thereof for  
~~delaying or inhibiting or suppressing the neurotoxicity of amyloid  $\beta$ -peptide or fragment thereof,~~  
~~comprising the step of administering the antibody of claim 26, thereby delaying or inhibiting or~~  
~~suppressing the neurotoxicity of amyloid  $\beta$ -peptide or fragment thereof.~~

53-54. (Canceled)

55. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and is targeted to the free N-terminus of amyloid  $\beta$ -peptide or a fragment thereof,  
wherein the first amino acid of said N-terminus is aspartate  
~~for delaying or inhibiting or suppressing~~  
~~the accumulation of an amyloid  $\beta$ -peptide or fragment thereof, comprising the step of administering~~  
~~the antibody of claim 28, thereby delaying or inhibiting or suppressing accumulation of amyloid  $\beta$~~   
~~peptide or fragment thereof in the brain.~~

56. (Currently amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and is targeted to the free N-terminus of amyloid  $\beta$ -peptide or a fragment thereof,  
wherein the first amino acid of said N-terminus is aspartate  
~~for delaying or inhibiting or suppressing~~  
~~the neurotoxicity of amyloid  $\beta$ -peptide or fragment thereof, comprising the step of administering the~~  
~~antibody of claim 28, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid  $\beta$~~   
~~peptide or fragment thereof.~~

57-58. (Canceled)

59. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and targeted to a free N-terminus of an amyloid  $\beta$  peptide fragment truncated at the C-terminus, N-terminus or both the N- and C-termini for delaying or inhibiting or suppressing the accumulation of an amyloid  $\beta$  peptide or fragment thereof, comprising the step of administering the antibody of claim 30, thereby delaying or inhibiting or suppressing accumulation of amyloid  $\beta$  peptide or fragment thereof in the brain.

60. (Currently amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and targeted to a free N-terminus of an amyloid  $\beta$  peptide fragment truncated at the C-terminus, N-terminus or both the N- and C-termini for delaying or inhibiting or suppressing the neurotoxicity of amyloid  $\beta$  peptide or fragment thereof, comprising the step of administering the antibody of claim 30, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid  $\beta$  peptide or fragment thereof.

61-62. (Canceled)

63. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and targeted to the free C-terminus of the amyloid  $\beta$ -peptide A $\beta$ 1-39, A $\beta$ 1-40, A $\beta$ 1-41, or A $\beta$ 1-43 for delaying or inhibiting or suppressing the accumulation of an amyloid  $\beta$  peptide or fragment thereof, comprising the step of administering the antibody of claim 32, thereby delaying or inhibiting or suppressing accumulation of amyloid  $\beta$  peptide or fragment thereof in the brain.

64. (Currently amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and targeted to the free C-terminus of the amyloid  $\beta$ -peptide A $\beta$ 1-39, A $\beta$ 1-40, A $\beta$ 1-41, or A $\beta$ 1-43 for delaying or inhibiting or suppressing the neurotoxicity of amyloid  $\beta$  peptide or fragment thereof, comprising the step of administering the antibody of claim 32, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid  $\beta$  peptide or fragment thereof.

65-66. (Cancelled)

67. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and targeted to a free C-terminus of an amyloid  $\beta$  peptide fragment truncated at the C-terminus, N-terminus or both the N- and C-termini for delaying or inhibiting or suppressing the accumulation of an amyloid  $\beta$  peptide or fragment thereof, comprising the step of administering the



~~antibody of claim 34, thereby delaying or inhibiting or suppressing accumulation of amyloid  $\beta$  peptide or fragment thereof in the brain.~~

68. (Currently Amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and targeted to a free C-terminus of an amyloid  $\beta$  peptide fragment truncated at the C-terminus, N-terminus or both the N- and C-termini ~~for delaying or inhibiting or suppressing the neurotoxicity of amyloid  $\beta$  peptide or fragment thereof, comprising the step of administering the antibody of claim 34, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid  $\beta$  peptide or fragment thereof.~~

70. (Canceled)

71. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and is targeted to the free C-terminus of the amyloid  $\beta$ - peptide A $\beta$ 1-42 ~~for delaying or inhibiting or suppressing the accumulation of an amyloid  $\beta$  peptide or fragment thereof, comprising the step of administering the antibody of claim 36, thereby delaying or inhibiting or suppressing accumulation of amyloid  $\beta$  peptide or fragment thereof in the brain.~~

72. (Currently amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and is targeted to the free C-terminus of the amyloid  $\beta$ - peptide A $\beta$ 1-42 ~~for delaying or inhibiting or suppressing the neurotoxicity of amyloid  $\beta$  peptide or fragment thereof, comprising the step of administering the antibody of claim 36, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid  $\beta$  peptide or fragment thereof.~~